RS51692B - 1,3-DIHYDROIMIDAZOL-2-TION DERIVATIVES AS DOPAMINE-BETA-HYDROXYLASE INHIBITORS - Google Patents

1,3-DIHYDROIMIDAZOL-2-TION DERIVATIVES AS DOPAMINE-BETA-HYDROXYLASE INHIBITORS

Info

Publication number
RS51692B
RS51692B RS20110165A RSP20110165A RS51692B RS 51692 B RS51692 B RS 51692B RS 20110165 A RS20110165 A RS 20110165A RS P20110165 A RSP20110165 A RS P20110165A RS 51692 B RS51692 B RS 51692B
Authority
RS
Serbia
Prior art keywords
alkyl
halogen
term
group
aryl
Prior art date
Application number
RS20110165A
Other languages
English (en)
Serbian (sr)
Inventor
Patrício Manuel Vieira Araújo SOARES DA SILVA
David Alexander Learmonth
Alexander Beliaev
Original Assignee
Bial-Portela & Ca S.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38198874&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=RS51692(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bial-Portela & Ca S.A. filed Critical Bial-Portela & Ca S.A.
Publication of RS51692B publication Critical patent/RS51692B/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
RS20110165A 2007-05-08 2008-05-06 1,3-DIHYDROIMIDAZOL-2-TION DERIVATIVES AS DOPAMINE-BETA-HYDROXYLASE INHIBITORS RS51692B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0708818.0A GB0708818D0 (en) 2007-05-08 2007-05-08 Compounds

Publications (1)

Publication Number Publication Date
RS51692B true RS51692B (en) 2011-10-31

Family

ID=38198874

Family Applications (1)

Application Number Title Priority Date Filing Date
RS20110165A RS51692B (en) 2007-05-08 2008-05-06 1,3-DIHYDROIMIDAZOL-2-TION DERIVATIVES AS DOPAMINE-BETA-HYDROXYLASE INHIBITORS

Country Status (30)

Country Link
US (5) US8481582B2 (es)
EP (1) EP2155731B1 (es)
JP (1) JP5559677B2 (es)
KR (1) KR101598482B1 (es)
CN (1) CN101687858B (es)
AR (2) AR066457A1 (es)
AT (1) ATE499367T1 (es)
AU (1) AU2008246443B2 (es)
BR (1) BRPI0811275B8 (es)
CA (1) CA2686387C (es)
CL (1) CL2008001321A1 (es)
CY (1) CY1111517T1 (es)
DE (1) DE602008005141D1 (es)
DK (1) DK2155731T3 (es)
ES (1) ES2360841T3 (es)
GB (1) GB0708818D0 (es)
HK (1) HK1142898A1 (es)
HR (1) HRP20110253T1 (es)
IL (1) IL201921A (es)
MX (1) MX2009012041A (es)
NO (1) NO20093275L (es)
NZ (1) NZ580962A (es)
PL (1) PL2155731T3 (es)
RS (1) RS51692B (es)
RU (1) RU2501796C2 (es)
SI (1) SI2155731T1 (es)
TW (1) TWI458722B (es)
UA (1) UA104844C2 (es)
WO (1) WO2008136695A1 (es)
ZA (1) ZA200908612B (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0708818D0 (en) 2007-05-08 2007-06-13 Portela & Ca Sa Compounds
US9212130B2 (en) * 2010-08-10 2015-12-15 Shionogi & Co., Ltd. Heterocyclic derivative and pharmaceutical composition comprising the same
CN103380128B (zh) * 2010-12-22 2017-03-01 拜欧波尔特拉及正大有限公司 晶型及其制备方法
EP2726454B1 (en) 2011-06-29 2018-01-24 Bial-Portela & CA, S.A. Process
IN2015DN04089A (es) * 2012-11-14 2015-10-09 BIAL PORTELA & Cª S A
CN103356671B (zh) * 2013-06-24 2015-11-25 顾祥茂 Houttuynoid C在制备治疗或预防慢性心衰的药物中的应用
GB201316410D0 (en) 2013-09-13 2013-10-30 Bial Portela & Ca Sa Processes for preparing peripherally-selective inhibitors of dopamine-?-hydroxylase and intermediates for use therein
JOP20190049A1 (ar) 2016-09-23 2019-03-20 Bial Portela & C? S A مثبطات دوبامين-b-هيدروكسيلاز
EP3681882A1 (en) 2017-09-13 2020-07-22 Amgen Inc. Bisamide sarcomere activating compounds and uses thereof
CA3082337A1 (en) 2017-12-04 2019-06-13 Bial - Portela & Ca, S.A. Dopamine-b-hydroxylase inhibitors
GB201810395D0 (en) * 2018-06-25 2018-08-08 Bial Portela & Ca Sa Formulations comprising dopamine-beta-hydroxylase inhibitors and methods for their preparation
SG11202104423XA (en) * 2018-11-12 2021-05-28 Immunogen Inc Methods of preparing cytotoxic benzodiazepine derivatives
GB201908044D0 (en) 2019-06-05 2019-07-17 Bial Portela & Ca Sa Dopamine-B-Hydroxylase inhibitors

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4217347A (en) * 1977-12-27 1980-08-12 E. R. Squibb & Sons, Inc. Method of treating hypertension and medicaments therefor
US4962128A (en) * 1989-11-02 1990-10-09 Pfizer Inc. Method of treating anxiety-related disorders using sertraline
US5298497A (en) * 1990-05-15 1994-03-29 E. R. Squibb & Sons, Inc. Method for preventing onset of hypertension employing a cholesterol lowering drug
HUT76295A (en) 1994-04-26 1997-07-28 Syntex Inc Imidazolyl- and triazolyl-thion derivatives, pharmaceutical compositions containing them and process for producing them
AR032711A1 (es) 2001-02-21 2003-11-19 Solvay Pharm Bv Derivados de fenilpiperazina, un metodo para la preparacion de los mismos y una composicion farmaceutica que los contiene
US7125904B2 (en) * 2002-10-11 2006-10-24 Portela & C.A., S.A. Peripherally-selective inhibitors of dopamine-β-hydroxylase and method of their preparation
GB2393958A (en) * 2002-10-11 2004-04-14 Portela & Ca Sa Peripherally-selective imidazole inhibitors of dopamine-beta-hydroxylase
GB0708818D0 (en) 2007-05-08 2007-06-13 Portela & Ca Sa Compounds

Also Published As

Publication number Publication date
WO2008136695A1 (en) 2008-11-13
BRPI0811275B8 (pt) 2021-05-25
ES2360841T3 (es) 2011-06-09
CA2686387C (en) 2015-06-30
TWI458722B (zh) 2014-11-01
JP5559677B2 (ja) 2014-07-23
BRPI0811275B1 (pt) 2020-01-07
ZA200908612B (en) 2010-11-24
UA104844C2 (uk) 2014-03-25
US20170369478A1 (en) 2017-12-28
AR112789A2 (es) 2019-12-11
CA2686387A1 (en) 2008-11-13
JP2010526136A (ja) 2010-07-29
KR20100017546A (ko) 2010-02-16
IL201921A (en) 2013-11-28
HK1142898A1 (en) 2010-12-17
CY1111517T1 (el) 2015-08-05
NO20093275L (no) 2010-02-04
CN101687858B (zh) 2012-12-26
IL201921A0 (en) 2010-06-16
GB0708818D0 (en) 2007-06-13
BRPI0811275A2 (pt) 2014-12-23
AR066457A1 (es) 2009-08-19
AU2008246443B2 (en) 2013-07-11
EP2155731A1 (en) 2010-02-24
PL2155731T3 (pl) 2011-07-29
CL2008001321A1 (es) 2008-12-26
US20190322648A1 (en) 2019-10-24
US20130345275A1 (en) 2013-12-26
DK2155731T3 (da) 2011-05-02
HRP20110253T1 (hr) 2011-05-31
SI2155731T1 (sl) 2011-05-31
US20210261533A1 (en) 2021-08-26
CN101687858A (zh) 2010-03-31
RU2501796C2 (ru) 2013-12-20
AU2008246443A1 (en) 2008-11-13
RU2009145270A (ru) 2011-06-20
TW200918525A (en) 2009-05-01
DE602008005141D1 (de) 2011-04-07
US8481582B2 (en) 2013-07-09
US9630951B2 (en) 2017-04-25
KR101598482B1 (ko) 2016-02-29
EP2155731B1 (en) 2011-02-23
NZ580962A (en) 2012-05-25
US20100137390A1 (en) 2010-06-03
AU2008246443A8 (en) 2010-01-07
ATE499367T1 (de) 2011-03-15
MX2009012041A (es) 2010-02-18

Similar Documents

Publication Publication Date Title
RS51692B (en) 1,3-DIHYDROIMIDAZOL-2-TION DERIVATIVES AS DOPAMINE-BETA-HYDROXYLASE INHIBITORS
RS53080B (en) AMINOPHOSPHORIC ACID ETHAR DERIVATIVE AND S1P RECEPTOR MODULATOR CONTAINING THE SAME AS THE ACTIVE INGREDIENT
EP1795536A4 (en) PHOSPHORAMIDITE COMPOUND AND PROCESS FOR THE PREPARATION OF OLIGO RNA
TW201129556A (en) Novel antiplatelet agent
RS52978B (en) FUSIONED AMINO PIRIDIN AS HSP90 INHIBITORS
RS52261B (en) AMIDOPHENOX INDASOLS AS A USEFUL C-MET INHIBITOR
MEP8409A (en) Fused heterocyclic compound
TNSN08372A1 (en) Heterocyclic amides for use as pharmaceuticals
TW200510381A (en) Novel 2-pyridinecarboxamide derivatives
HRP20110498T1 (hr) Azetidini kao inhibitori mek za liječenje proliferativnih bolesti
RS50980B (sr) Derivati n-hidroksiamida i njihova upotreba
RS50537B (sr) Derivati benzimidazola i njihovo korišćenje kao antagonista receptora a ii
ATE556058T1 (de) 1-(2h)-isochinolonderivat
RS53830B1 (en) INDASOLS SUBSTITUTED BY OXAZOLE AS PI3-KINASE INHIBITORS
MX2011010647A (es) Analogos de isoxasol-3 (2h)-ona como agentes terapeuticos.
MX2010008101A (es) Derivados de indol 2-carboxamidas y de azaindol 2-carboxamidas sustituidos con un silanilo, su preparacion y su aplicacion en terapeutica.
RS51226B (sr) Derivati azapeptida kao inhibitori hiv proteaze
TW200745058A (en) MMP-13 selective inhibitors
RS52881B (en) BENZAMIDINE COMPOUNDS USED AS HISTONAL DEACETYLASE INHIBITORS
RS53903B1 (en) ETHINYL DERIVATIVES AS POSITIVE MGLUR5 MODULATORS
RS53088B (en) LOW MOLECULAR TRP-P8 ACTIVITY MODULATORS
EA200500717A1 (ru) Новые соединения имидазопиридина, способ их получения и фармацевтические композиции, которые их содержат
TW200505899A (en) 4-substituted quinoline derivatives, method and intermediates for their preparation and pharmaceutical compositions containing them
TNSN07395A1 (en) Novel phenyl-pyridinyl-piperazine derivatives, a method for the production thereof and pharmaceutical compositions containing said derivatives
DK2000473T3 (da) Trehalose-forbindelse og lægemiddel omfattende forbindelsen